Knowledge

GcMAF

Source đź“ť

160:
In September 2018 Noakes pleaded guilty in UK to manufacturing a medicinal product without a manufacturer's licence, selling or supplying medicinal products without market authorisation, and money laundering, and sentenced to 15 months of jail. In April 2021 Noakes pleaded guilty in France to
847:
Toshio Inui, Kaori Makita, Hirona Miura, Akiko Matsuda, Daisuke Kuchiike, Kentaro Kubo, Martin Mette, Yoshihiro Uto, Takahito Nishikata, Hitoshi Hori And Norihiro Sakamoto (2014). "Case Report: A Breast Cancer Patient Treated With Gcmaf, Sonodynamic Therapy And Hormone Therapy".
123:
was granted. Retraction reasons also included methodological errors in the studies. The integrity of the research, conducted by Nobuto Yamamoto and colleagues, that originally prompted claims regarding cancer and HIV has been questioned.
46:
Once proclaimed a 'magic protein' capable of curing cancer, GcMAF has been proven ineffective. The case sheds light on how far scammers are willing to go to exploit desperate cancer patients and their families for financial gain.
534:
Yamamoto, Nobuto; Suyama, Hirofumi; Yamamoto, Nobuyuki; Ushijima, Naofumi (15 January 2008). "Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)".
951:
Toshio Inui, Oksana Kruglova, Olga Martyneko, Kostiantym Martyneko, Vadym Tieroshyn, Anatoli Gavrylov, Kentaro Kubo Borys Kutsyn, Alla Kubashko, Zoryana Veklych, Yurika Terashima, Martin Mette And Galyna Kutsyna (2023).
205:
The 2nd and 3rd generation GcMAF were developed by the Japanese organizations which hold the patents: in the USA (2014, 2016, 2017), Japan (2015), the EU (2016), Australia (2016), Israel (2018).
906:
Daisuke Kuchiike, Yoshihiro Uto, Hirotaka Mukai, Noriko Ishiyama, Chiaki Abe, Daichi Tanaka, Tomohito Kawai, Kentaro Kubo, Martin Mette, Toshio Inui, Yoshio Endo And Hitoshi Hori (2013).
877:
Toshio Inui, Daisuke Kuchiike, Kentaro Kubo, Martin Mette, Yoshihiro Uto, Hitoshi Hori And Norihiro Sakamoto (2013). "Clinical Experience Of Integrative Cancer Immunotherapy With Gcmaf".
954:"Effect Of Degalactosylated Bovine Glycoprotein Formulations Maf And M Сapsules On Lymphopenia And Clinical Outcomes In Hospitalized Covid-19 Patients: A Randomized Clinical Trial" 775: 388: 128: 490: 979: 937: 892: 863: 294: 1035: 1008:"United States Patent (10) Patent No.: Us 9,409,972 B2 Uto Et Al. (45) Date Of Patent: Pharmaceutical Composition And Method Of Preparing Same *Aug. 9, 2016" 168:
report detailed the activities of Amanda Mary Jewell, who sold GcMAF for years as a(n unlicensed) cure for several medical conditions, including cancer and
803:"Unlicensed medical 'cures' are flourishing in closed Facebook groups, where cancer treatments — and even surgery — are sold beyond the reach of the law" 692: 587: 520: 605:"Retraction Note to: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF" 243: 214: 288:
Malik, Suneil; Fu, Lei; Juras, David James; Karmali, Mohamed; Wong, Betty Y. L.; Gozdzik, Agnes; Cole, David E. C. (January–February 2013).
193:. Previous research efforts involved the isolation of Gc protein (1f1f subtype) from human serum through an affinity column modified with 779: 1050:"European Patent Specification Pharmaceutical Composition And Manufacturing Method Therefor Wo 2013/038997 (21.03.2013 Gazette 2013/12)" 396: 41:. It has been falsely promoted as a treatment for various medical conditions, but claims of its benefits are not supported by evidence. 116: 1022:"United States Patent Uto Et Al. Usoo9670268b2 Us 9,670,268 B2 *Jun. 6, 2017 Pharmaceutical Composition And Method Of Preparing Same" 994:"United States Patent Uto Et Al. Us008747919b2 Us 8,747,919 B2 Jun. 10, 2014 Pharmaceutical Composition And Method Of Preparing Same" 473: 908:"Degalactosylated/Desialylated Human Serum Containing Gcmaf Induces Macrophage Phagocytic Activity And In Vivo Antitumor Activity" 706: 1063: 1064:"Australian Government Ip Australia 2012309586 Pharmaceutical Composition And Manufacturing Method Therefor 2012-09-07 Granted" 802: 656: 140: 153:
In 2015 the UK Medicines and Healthcare products Regulatory Agency (MHRA) closed a factory in Milton, Cambridgeshire owned by
1097: 707:"Tracking retractions as a window into the scientific process Yet another study of widely touted cancer "cure" retracted" 345: 81: 427: 120: 65: 38: 161:
manufacturing and selling fake medicinal products and cosmetics by Internet and sentenced to 4 years of jail.
747: 119:
by the scientific journals in which they were published in 2014, officially due to irregularities in the way
1087: 732: 973: 931: 886: 857: 264: 115:
Three out of four of the original studies authored by Yamamoto (published between 2007 and 2009) were
521:"Press Release: Regulator warns against GcMAF made in unlicensed facility in Cambridgeshire - GOV.UK" 423:"Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF)" 112:
Since around 2008, GcMAF has been promoted as a cure for cancer, HIV, autism and other conditions.
1049: 1021: 1007: 993: 1092: 1082: 673: 560: 392: 132: 919: 636: 579: 552: 465: 446: 364: 321: 239: 136: 233: 189:
GcMAF initially conceptualized by Nobuto Yamamoto in 1991, has been researched as a possible
961: 665: 626: 616: 571: 544: 457: 436: 354: 311: 303: 190: 165: 150:
communicated serious concerns about published studies on GcMAF by Yamamoto and colleagues.
761: 495: 147: 631: 604: 953: 316: 289: 143:
enzyme (also known as nagalase), whose production might be increased in many cancers.
1076: 677: 57: 564: 290:"Common variants of the vitamin D binding protein gene and adverse health outcomes" 154: 97: 965: 776:"Cinq Britanniques condamnés pour la vente d'un médicament "miracle" sur internet" 307: 907: 93: 389:"'Cancer cured for good?' – Gc-MAF and the miracle cure (revised 25 July 2014)" 135:
has warned the public about spurious claims of clinical benefits, misleadingly
693:"Paper about widely touted but unapproved "cure" for cancer, autism retracted" 621: 85: 69: 61: 173: 923: 827: 640: 583: 556: 469: 450: 368: 325: 491:"The mysterious death of a doctor who peddled autism 'cures' to thousands" 359: 340: 27:
Protein produced by artificial modification of vitamin D-binding protein
603:
Yamamoto, N.; Suyama, H.; Nakazato, H.; Yamamoto, N.; Koga, Y. (2014).
523:. Medicines and Healthcare products Regulatory Agency. 3 February 2015. 157:' company Immuno Biotech that manufactured GcMAF for cancer treatment. 89: 669: 575: 548: 461: 441: 422: 17: 421:
Yamamoto, Nobuto; Ushijima, Naofumi; Koga, Yoshihiko (January 2009).
169: 77: 73: 101: 197:
GcMAF was enzymatically derived from the isolated Gc protein.
96:, and one of their functions is to make macrophages become 1036:"Japan Platform For Patent Information Wo-A1-2013/038997" 185:
Gc protein-derived macrophage-activating factor (GcMAF).
778:(in French). Notretemps. 15 April 2021. Archived from 762:"Cancer 'cure' boss David Noakes jailed for 15 months" 235:
Galactosidases — Advances in Research and Application
382: 380: 378: 129:
Medicines and Healthcare products Regulatory Agency
259: 257: 255: 68:(the Gc protein), which is naturally promoted by 295:Critical Reviews in Clinical Laboratory Sciences 238:. Scholarly Editions. 21 June 2013. p. 52. 416: 414: 44: 35:Gc protein-derived macrophage activating factor 8: 978:: CS1 maint: multiple names: authors list ( 936:: CS1 maint: multiple names: authors list ( 891:: CS1 maint: multiple names: authors list ( 862:: CS1 maint: multiple names: authors list ( 283: 281: 52:Public warning issued by the Anticancer Fund 37:) is a protein produced by modification of 630: 620: 440: 358: 341:"The many faces of macrophage activation" 315: 265:"GcMAF: a story of exploitation and lies" 828:"Investigation over cancer 'cure' GcMAF" 225: 80:cells). The resulting protein may be a 971: 929: 884: 855: 515: 513: 215:List of ineffective cancer treatments 7: 489:Miller, Michael E. (16 July 2015). 733:"UK's MHRA shuts down GcMAF plant" 339:Mosser, David M. (February 2003). 201:New Generation of GcMAF from Japan 25: 748:"Man behind GcMAF is facing jail" 746:Mann, Nick (27 September 2018). 609:Cancer Immunology, Immunotherapy 60:, GcMAF results from sequential 657:International Journal of Cancer 537:International Journal of Cancer 141:alpha-N-acetylgalactosaminidase 88:that control the expression of 664:(6): 1509. 15 September 2014. 387:Arney, Kat (3 December 2008). 1: 691:Ivan Oransky (25 July 2014). 267:. Anticancer Fund. 2017-12-08 346:Journal of Leukocyte Biology 308:10.3109/10408363.2012.750262 82:macrophage activating factor 966:10.21203/rs.3.rs-2879067/v1 428:Journal of Medical Virology 1114: 826:Evans, Ruth (2016-10-16). 801:Porter, Tom (2019-10-18). 735:. FDA News. 1 March 2015. 622:10.1007/s00262-014-1616-x 139:on reduced levels of the 66:vitamin D-binding protein 39:vitamin D-binding protein 764:. BBC. 27 November 2018. 180:First Generation GcMAF 49: 1098:Health fraud products 570:(Retracted, see 456:(Retracted, see 195:25-hydroxyvitamin D3. 146:In 2014 the Belgian 912:Anticancer Research 879:Anticancer Research 850:Anticancer Research 360:10.1189/jlb.0602325 84:(MAF). MAFs are 695:. Retractionwatch. 399:on 17 October 2014 393:Cancer Research UK 172:. Jewell is not a 133:Cancer Research UK 92:on the surface of 750:. Guernsey Press. 670:10.1002/ijc.29014 576:10.1002/ijc.29014 549:10.1002/ijc.23107 462:10.1002/jmv.24060 442:10.1002/jmv.21376 245:978-1-4816-8801-7 16:(Redirected from 1105: 1068: 1067: 1060: 1054: 1053: 1046: 1040: 1039: 1032: 1026: 1025: 1018: 1012: 1011: 1004: 998: 997: 990: 984: 983: 977: 969: 948: 942: 941: 935: 927: 918:(7): 2881–2885. 903: 897: 896: 890: 882: 881:: 33, 2917-2920. 874: 868: 867: 861: 853: 852:: 34, 4589-4594. 844: 838: 837: 835: 834: 823: 817: 816: 814: 813: 807:Business Insider 798: 792: 791: 789: 787: 782:on 17 April 2021 772: 766: 765: 758: 752: 751: 743: 737: 736: 729: 723: 722: 720: 718: 711:Retraction Watch 703: 697: 696: 688: 682: 681: 651: 645: 644: 634: 624: 600: 594: 593: 589:Retraction Watch 568: 531: 525: 524: 517: 508: 507: 505: 503: 486: 480: 479: 475:Retraction Watch 454: 444: 418: 409: 408: 406: 404: 395:. Archived from 384: 373: 372: 362: 336: 330: 329: 319: 285: 276: 275: 273: 272: 261: 250: 249: 230: 191:cancer treatment 166:Business Insider 121:ethical approval 53: 21: 1113: 1112: 1108: 1107: 1106: 1104: 1103: 1102: 1073: 1072: 1071: 1062: 1061: 1057: 1048: 1047: 1043: 1034: 1033: 1029: 1020: 1019: 1015: 1006: 1005: 1001: 992: 991: 987: 970: 958:Research Square 950: 949: 945: 928: 905: 904: 900: 883: 876: 875: 871: 854: 846: 845: 841: 832: 830: 825: 824: 820: 811: 809: 800: 799: 795: 785: 783: 774: 773: 769: 760: 759: 755: 745: 744: 740: 731: 730: 726: 716: 714: 705: 704: 700: 690: 689: 685: 653: 652: 648: 602: 601: 597: 569: 533: 532: 528: 519: 518: 511: 501: 499: 496:Washington Post 488: 487: 483: 455: 420: 419: 412: 402: 400: 386: 385: 376: 338: 337: 333: 287: 286: 279: 270: 268: 263: 262: 253: 246: 232: 231: 227: 223: 211: 203: 182: 148:Anticancer Fund 110: 62:deglycosylation 55: 51: 28: 23: 22: 15: 12: 11: 5: 1111: 1109: 1101: 1100: 1095: 1090: 1088:Human proteins 1085: 1075: 1074: 1070: 1069: 1055: 1041: 1027: 1013: 999: 985: 943: 898: 869: 839: 818: 793: 767: 753: 738: 724: 698: 683: 654:"Retraction". 646: 595: 543:(2): 461–467. 526: 509: 481: 410: 374: 353:(2): 209–212. 331: 277: 251: 244: 224: 222: 219: 218: 217: 210: 207: 202: 199: 181: 178: 174:medical doctor 109: 106: 43: 26: 24: 14: 13: 10: 9: 6: 4: 3: 2: 1110: 1099: 1096: 1094: 1091: 1089: 1086: 1084: 1081: 1080: 1078: 1065: 1059: 1056: 1051: 1045: 1042: 1037: 1031: 1028: 1023: 1017: 1014: 1009: 1003: 1000: 995: 989: 986: 981: 975: 967: 963: 959: 955: 947: 944: 939: 933: 925: 921: 917: 913: 909: 902: 899: 894: 888: 880: 873: 870: 865: 859: 851: 843: 840: 829: 822: 819: 808: 804: 797: 794: 781: 777: 771: 768: 763: 757: 754: 749: 742: 739: 734: 728: 725: 712: 708: 702: 699: 694: 687: 684: 679: 675: 671: 667: 663: 659: 658: 650: 647: 642: 638: 633: 628: 623: 618: 614: 610: 606: 599: 596: 591: 590: 585: 581: 577: 573: 566: 562: 558: 554: 550: 546: 542: 538: 530: 527: 522: 516: 514: 510: 498: 497: 492: 485: 482: 477: 476: 471: 467: 463: 459: 452: 448: 443: 438: 434: 430: 429: 424: 417: 415: 411: 398: 394: 390: 383: 381: 379: 375: 370: 366: 361: 356: 352: 348: 347: 342: 335: 332: 327: 323: 318: 313: 309: 305: 301: 297: 296: 291: 284: 282: 278: 266: 260: 258: 256: 252: 247: 241: 237: 236: 229: 226: 220: 216: 213: 212: 208: 206: 200: 198: 196: 192: 187: 186: 179: 177: 175: 171: 167: 162: 158: 156: 151: 149: 144: 142: 138: 134: 130: 125: 122: 118: 113: 107: 105: 103: 99: 95: 91: 87: 83: 79: 75: 71: 67: 63: 59: 58:Biochemically 54: 48: 42: 40: 36: 32: 19: 1058: 1044: 1030: 1016: 1002: 988: 974:cite journal 957: 946: 932:cite journal 915: 911: 901: 887:cite journal 878: 872: 858:cite journal 849: 842: 831:. Retrieved 821: 810:. Retrieved 806: 796: 784:. Retrieved 780:the original 770: 756: 741: 727: 715:. Retrieved 713:. 2014-10-10 710: 701: 686: 661: 655: 649: 615:(12): 1349. 612: 608: 598: 588: 586:,   540: 536: 529: 500:. Retrieved 494: 484: 474: 472:,   435:(1): 16–26. 432: 426: 401:. Retrieved 397:the original 350: 344: 334: 299: 293: 269:. Retrieved 234: 228: 204: 194: 188: 184: 183: 163: 159: 155:David Noakes 152: 145: 126: 114: 111: 108:False claims 56: 50: 45: 34: 30: 29: 403:10 February 302:(1): 1–22. 94:macrophages 86:lymphokines 70:lymphocytes 1077:Categories 833:2019-11-14 812:2019-11-14 271:2018-07-28 221:References 1093:Vitamin D 1083:Cytokines 678:221774191 502:26 August 117:retracted 98:cytotoxic 924:23780974 786:17 April 641:25297451 632:11028656 584:25180398 565:15258428 557:17935130 470:25328930 451:19031451 369:12554797 326:23427793 209:See also 90:antigens 717:28 July 317:3613945 164:A 2019 127:The UK 64:of the 922:  676:  639:  629:  582:  578:, 563:  555:  468:  464:, 449:  367:  324:  314:  242:  170:autism 102:tumors 18:Gc-MAF 674:S2CID 561:S2CID 137:based 31:GcMAF 980:link 938:link 920:PMID 893:link 864:link 788:2021 719:2015 637:PMID 580:PMID 553:PMID 504:2015 466:PMID 447:PMID 405:2015 365:PMID 322:PMID 240:ISBN 131:and 76:and 33:(or 962:doi 666:doi 662:135 627:PMC 617:doi 572:doi 545:doi 541:122 458:doi 437:doi 355:doi 312:PMC 304:doi 100:to 1079:: 976:}} 972:{{ 960:. 956:. 934:}} 930:{{ 916:33 914:. 910:. 889:}} 885:{{ 860:}} 856:{{ 805:. 709:. 672:. 660:. 635:. 625:. 613:63 611:. 607:. 559:. 551:. 539:. 512:^ 493:. 445:. 433:81 431:. 425:. 413:^ 391:. 377:^ 363:. 351:73 349:. 343:. 320:. 310:. 300:50 298:. 292:. 280:^ 254:^ 176:. 104:. 1066:. 1052:. 1038:. 1024:. 1010:. 996:. 982:) 968:. 964:: 940:) 926:. 895:) 866:) 836:. 815:. 790:. 721:. 680:. 668:: 643:. 619:: 592:) 574:: 567:. 547:: 506:. 478:) 460:: 453:. 439:: 407:. 371:. 357:: 328:. 306:: 274:. 248:. 78:T 74:B 72:( 20:)

Index

Gc-MAF
vitamin D-binding protein
Biochemically
deglycosylation
vitamin D-binding protein
lymphocytes
B
T
macrophage activating factor
lymphokines
antigens
macrophages
cytotoxic
tumors
retracted
ethical approval
Medicines and Healthcare products Regulatory Agency
Cancer Research UK
based
alpha-N-acetylgalactosaminidase
Anticancer Fund
David Noakes
Business Insider
autism
medical doctor
cancer treatment
List of ineffective cancer treatments
Galactosidases — Advances in Research and Application
ISBN
978-1-4816-8801-7

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑